RecruitingPhase 3NCT07562152

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Sponsor

Immuneering Corporation

Enrollment

510 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic Pancreatic Ductal Adenocarcinoma Pancreatic Adenocarcinoma PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Metastatic

Summary

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atebimetinib, a drug called GnP, and others for people with pdac, pdac - pancreatic ductal adenocarcinoma, and other related conditions. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtebimetinib

Once daily oral tablets

DRUGGnP

Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion

DRUGmGnP

Biweekly intravenous infusions of chemotherapy (gemcitabine and nab-paclitaxel)

Locations(31)

City of Hope

Phoenix, Arizona, United States

City of Hope

Duarte, California, United States

Medical Oncology Hematology Consultants

Newark, Delaware, United States

Hematology Oncology Associates of the Treasure Coast

Port Saint Lucie, Florida, United States

Florida Cancer Specialists - South

Sarasota, Florida, United States

Florida Cancer Specialists - North

St. Petersburg, Florida, United States

Florida Cancer Specialists - East

West Palm Beach, Florida, United States

Piedmont Healthcare

Atlanta, Georgia, United States

Illinois Cancer Specialists

Arlington Heights, Illinois, United States

City of Hope

Chicago, Illinois, United States

OSF Medical Center

Peoria, Illinois, United States

Maryland Oncology

Columbia, Maryland, United States

Missouri Cancer Associates

Columbia, Missouri, United States

Comprehensive Cancer Centers

Las Vegas, Nevada, United States

Regional Cancer Care

Belleville, New Jersey, United States

NYU Langone Health

New York, New York, United States

Taylor Cancer Research Center

Maumee, Ohio, United States

Willamette Valley Cancer Institute

Eugene, Oregon, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

West Cancer Center

Germantown, Tennessee, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Texas Oncology - West Texas

Abilene, Texas, United States

Texas Oncology - Austin

Austin, Texas, United States

Texas Oncology - San Antonio

San Antonio, Texas, United States

Texas Oncology Gulf Coast

Webster, Texas, United States

Blue Ridge Cancer Care

Blacksburg, Virginia, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Northwest Cancer Specialists

Vancouver, Washington, United States

Calvary Mater Newcastle

Waratah, New South Wales, Australia

Genesiscare

Waratah, New South Wales, Australia

Icon Cancer Centre - Chermside

Chermside, Queensland, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07562152

Related Trials

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT0725223260 locations

Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain

NCT076363821 location

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

NCT064116911 location

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT0465706882 locations

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT0656219229 locations